<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">CDCST</journal-id><journal-title-group><journal-title>China Daily Chemical Science Technology</journal-title></journal-title-group><issn>2997-7096</issn><eissn>2997-710X</eissn><publisher><publisher-name>Art and Technology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.61369/CDCST.2026010015</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>罗马洋甘菊挥发油脂质体凝胶对特应性皮炎的治疗作用研究</title><url>https://artdesignp.com/journal/CDCST/3/1/10.61369/CDCST.2026010015</url><author>程军,张大存,汪春风,胡晗璐,钱雪,陈斌,陈国庆</author><pub-date pub-type="publication-year"><year>2026</year></pub-date><volume>3</volume><issue>1</issue><history><date date-type="pub"><published-time>2026-03-05</published-time></date></history><abstract>本研究旨在制备白及多糖包裹的罗马洋甘菊挥发油脂质体凝胶（CNVO-LG），探究其对小鼠AD的治疗效果。结果表明，罗马洋甘菊挥发油脂质体平均粒径145.6 nm，多分散系数为0.195，大小均一；脂质体凝胶呈疏松多孔网络结构。小鼠AD模型试验表明，CNVO-LG可显著改善AD小鼠的皮肤损状态，同时有效抑制AD小鼠皮肤和血清中IgG、TNF&amp;alpha;、IL-4以及IFN&amp;gamma;等细胞因子水平。综上，罗马洋甘菊挥发油脂质体凝胶在治疗AD方面展现出较大应用潜力，为AD治疗提供了潜在方案。</abstract><keywords>罗马洋甘菊,挥发油,脂质体凝胶,特应性皮炎</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>[1]LYONS J J, MILNER J D, STONE K D. Atopic dermatitis in children: clinical features, pathophysiology, and treatment [J]. Immunol Allergy Clin North Am, 2015, 35(1): 161-183.[2]NAKAHARA T, KIDO-NAKAHARA M, TSUJI G, et al. Basics and recent advances in the pathophysiology of atopic dermatitis [J]. J Dermatol, 2021, 48(2): 130-139.[3]GUO Y, ZHANG H, LIU Q, et al. Phenotypic analysis of atopic dermatitis in children aged 1-12 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence [J]. J Eur Acad Dermatol Venereol, 2019, 33(8): 1569-1576.[4]DAVID BOOTHE W, TARBOX J A, TARBOX M B. Atopic Dermatitis: Pathophysiology [J]. Adv Exp Med Biol, 2017, 1027: 21-37.[5]SOLOMON I, ILIE M A, DRAGHICI C, et al. The impact of lifestyle factors on evolution of atopic dermatitis: An alternative approach [J]. Exp Ther Med, 2019, 17(2): 1078-1084.[6]THYSSEN J P, VESTERGAARD C, DELEURAN M, et al. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis [J]. J Eur Acad Dermatol Venereol,2020, 34(12): e839-e842.[7]BARNES L, KAYA G, ROLLASON V. Topical corticosteroid-induced skin atrophy: a comprehensive review [J]. Drug Saf, 2015, 38(5):493-509.[8]付春雪. 黑龙江罗马洋甘菊挥发油和纯露成分分析及抑菌实验研究 [D]. 佳木斯大学, 2019.[9]GALV&amp;atilde;O L C, FURLETTI V F, BERSAN S M, et al. Antimicrobial Activity of Essential Oils against Streptococcus mutans and their Antiproliferative Effects [J]. Evid Based Complement Alternat Med, 2012:751435.[10]CHEN Z, CHENG L, HE Y, et al. Extraction, characterization, utilization as wound dressing and drug delivery of Bletilla striata polysaccharide: A review [J]. Int J Biol Macromol, 2018, 120(Pt B): 2076-2085.[11]HE X, WANG X, FANG J, et al. Bletilla striata: Medicinal uses, phytochemistry and pharmacological activities [J]. J Ethnopharmacol,2017, 195: 20-38.[12] 马世宏, 金玲, 揭邃, 等. 白芨-丹皮酚包合物在化妆品中的应用研究 [J]. 日用化学品科学, 2009, 32(06): 30-33.[13] 庞素秋, 王国权, 吴双, 等. 白及多糖对大鼠深Ⅱ度烫伤创面的保护作用 [J]. 中药材, 2013, 36(11): 1819-1823.[14]Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis [J].Dermatology, 1993, 186(1): 23-31.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
